Content is available to registered users only. Registration is free.
Register now, or if you’ve already registered, log in.
Jason Wermers, CRTonline.org
PHILADELPHIA – The experimental antiplatelet drug compound CG-0255 demonstrated several advantages over clopidogrel and was well-tolerated by patients, according to new phase I trial results.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details